TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Opyl Ltd. ( (AU:PKY) ) has provided an update.
Pathkey.AI Ltd has announced the conversion of financial obligations into shares for its directors, Mr. Antanas Guoga and Mr. Damon Rasheed, subject to shareholder approval. This move involves converting a loan from Mr. Guoga and technical consulting fees for Mr. Rasheed into fully paid ordinary shares, aligning the directors’ interests with shareholders and preserving cash resources. These transactions are in line with ASX Listing Rule 10.11 and reflect the company’s strategic approach to maintaining financial stability while engaging its leadership in its growth trajectory.
More about Opyl Ltd.
Pathkey.AI Limited (ASX: PKY) is an Australian technology company specializing in artificial intelligence to enhance the efficiency, success, and transparency of clinical trials. Its primary product, TrialKey, is an AI-powered decision-support tool that predicts clinical trial success and aids in optimizing trial design and planning. The company is focused on transforming drug development by reducing risk, improving resource allocation, and fostering data-driven innovation in the life sciences sector.
Average Trading Volume: 1,101,696
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.05M
For detailed information about PKY stock, go to TipRanks’ Stock Analysis page.